See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the “ecosystem” of microbes populating the intestines—linked to the development of IBD.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7204351-crohn-s-colitis-foundation-of-america-gut-bacteria-new-strategies-to-prevent/
GSK Consumer Healthcare and FLONASE® Sensimist™ Allergy Relief, along with Emmy® Award-winning choreographer and entertainer Derek Hough, today announced the launch of the 2017 Greater American Road Trip featuring social media’s favorite family, the Eh Bees. On Thursday, March 16, the Eh Bee family will begin their coast-to-coast journey to rethink allergy treatment and leave each city a little bit greater than they found it.
Derek, along with Eh Bee family members Mama Bee and her son Mr. Monkey, all suffer from allergies, but are determined to be greater than their itchy, watery eyesi and congested noses with the help of new FLONASE Sensimist. After kicking off the journey together in Los Angeles, Derek will challenge the Eh Bees and their allergies as they partner with local organizations throughout some of the worst allergy cities in the country.
To view the multimedia release go to:
https://www.multivu.com/players/English/8061451-flonase-greater-american-road-trip-derek-hough-eh-bee/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
The Prostate Cancer Foundation (PCF) announces the launch of the “Step Up for Blue” Campaign for Prostate Cancer Awareness Month. The campaign honors the millions of men and their families touched by prostate cancer worldwide.
“Step Up for Blue” focuses on elevating critical issues to inspire, energize, and accelerate actions that lead to greater awareness, new therapies, and fewer deaths from prostate cancer. It will run through the duration of September.
To view the multimedia release go to:
http://www.multivu.com/players/English/7729253-pcf-step-up-for-blue-prostate-cancer/
Nuelle™, a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women, announces today its Indiegogo campaign to raise awareness and funding for the company’s first product launch Fiera® Arouser for Her™.
In the US, roughly 46% of all American women, aged 18 – 70 have a sexual concern. Among committed couples, intimacy is important for both the health of the relationship and personal wellbeing. Sex, however, is often a tough subject to broach with partners, health care professionals and friends alike. Through its partnership with Indiegogo, Nuelle aims to normalize the conversation about women’s sexual wellbeing and the impact on quality of life, while educating couples about Fiera® Arouser for Her™ and its proven technology to scientifically enhance arousal and desire, naturally.
Co-created with women and healthcare professionals to bring back excitement to connect sexually with her partner, Nuelle’s Fiera® Arouser for Her™ is the first wearable intimacy enhancer used in advance of a sexual experience that is proven to ignite arousal and increase desire among women. In a study (after four weeks of using Fiera), 87% of women said they felt “in the mood” for sex and 83% enjoyed engaging in sex.*
To view the multimedia release go to:
http://www.multivu.com/players/English/7750851-nuelle-indiegogo-fiera-arouser-for-her/
USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
Long before it's time for hospice care, many people with serious illness can benefit from palliative care but don’t realize it. Sometimes referred to as “comfort care,” palliative care is a specialized approach to the treatment of patients with a serious or life-threatening illness. Palliative care has helped Deadra Gladden get her life back through symptom management and support from Samaritan Healthcare & Hospice, Marlton, N.J.
In May of 2014 Deadra, age 28, was in the hospital, feeling hopeless and in excruciating pain due to lupus, a disease she has been battling for over half her young life. Deadra's doctors told her family it was time to call hospice. But after consulting with a nurse from Samaritan Healthcare and Hospice, a palliative care team was brought in instead.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the results of a social experiment in which 160 participants (80 allergy sufferers and 80 non-sufferers) wore a wearable device for 30 days to track their sleep and activity. The first-of-its-kind experiment found allergy symptoms can impact various elements of sufferers’ lives, including both the quality of their sleep and their daytime activities. Xyzal is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to Wise Up about the importance of managing their allergies this spring, so they can have a better night’s sleep and Rise Up in the morning to take on the day.
To view the multimedia release go to:
https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
